Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in vaccine delivery systems.

D T O'Hagan1

  • 1Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. derek_o'hagan@chiron.com

Current Drug Targets. Infectious Disorders
|November 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs.

Vaccine·2013
Same author

The mechanism of action of MF59 - an innately attractive adjuvant formulation.

Vaccine·2012
Same author

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

Clinical pharmacology and therapeutics·2007
Same author

Delivery systems and adjuvants for oral vaccines.

Expert opinion on drug delivery·2006
Same author

Recent advances in immunological adjuvants: the development of particulate antigen delivery systems.

Expert opinion on investigational drugs·2005
Same author

Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract.

Journal of drug targeting·2004
Same journal

Discoveries of Tat-TAR interaction inhibitors for HIV-1.

Current drug targets. Infectious disorders·2006
Same journal

Chemosensitizers in drug transport mechanisms involved in protozoan resistance.

Current drug targets. Infectious disorders·2006
Same journal

Neuraminidase inhibitors as antiviral agents.

Current drug targets. Infectious disorders·2006
Same journal

Developments in antiviral drug design, discovery and development in 2004.

Current drug targets. Infectious disorders·2006
Same journal

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Current drug targets. Infectious disorders·2005
Same journal

The molecular basis for the mode of action of bicyclomycin.

Current drug targets. Infectious disorders·2005
See all related articles

New vaccine adjuvants, including delivery systems and immunostimulatory agents, are crucial for enhancing immunogenicity. Further research into their mechanisms will enable the development of novel vaccines against challenging diseases like HIV.

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Background:

  • Next-generation vaccines (recombinant protein, DNA) show reduced reactogenicity but also lower immunogenicity compared to traditional vaccines.
  • There is a critical need for advanced vaccine adjuvants to improve immune responses.
  • Adjuvants are classified into vaccine delivery systems and immunostimulatory adjuvants based on their action mechanisms.

Purpose of the Study:

  • This review focuses on recent advancements in vaccine delivery systems.
  • To explore the potential of novel adjuvants and delivery system combinations for improved vaccine efficacy.
  • To highlight the need for further research into adjuvant mechanisms for developing new vaccines.

Main Methods:

  • Review of recent developments in vaccine delivery systems (emulsions, microparticles, liposomes, etc.).

Related Experiment Videos

  • Discussion of immunostimulatory adjuvants derived from pathogen-associated molecular patterns (PAMPs).
  • Examination of combined strategies using delivery systems and immunostimulatory agents.

    • Main Results:

    • Vaccine delivery systems primarily function to target antigens to antigen-presenting cells (APCs).
    • Immunostimulatory adjuvants activate innate immunity, which in turn shapes the acquired immune response.
    • Combining delivery systems with immunostimulatory agents can enhance adjuvant delivery to APCs.

    Conclusions:

    • Further elucidation of adjuvant mechanisms is essential for rational development of more effective vaccines.
    • Potent adjuvants could facilitate the creation of vaccines against pathogens like HIV.
    • Novel adjuvant and delivery system combinations may enable mucosal vaccine delivery.